Results 121 to 130 of about 249 (133)
P0334 AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjects
A Sáez-Borderías, Tim Van Kaem, J Alberti, Pieter-Jan Stiers, Caroline Sabadie, R. Van Heeswijk, T Senso, B Pampín, R. Bosser, P. Wiesel +9 moreopenalex +1 more source